Explore our certified CRO and CDMO analytical pipelines engineered to eliminate botanical cytotoxicity, screen adverse side effects, and optimize pharmaceutical-grade purity.
Harnessing world-class phytochemistry infrastructure, proprietary molecular fingerprinting, and integrated supply lines to de-risk active ingredient portfolios.
China holds over 11,000 documented medicinal plant species. Our Changsha central extraction and pilot CDMO hub leverages geographic microclimates across Sichuan, Yunnan, Hunan, and Guizhou. By auditing raw cultivars at the point of origin, our factories isolate therapeutic secondary metabolites while pre-emptively filtering out heavy metals, pesticide residues, and endogenous plant toxins (e.g., pyrrolizidine alkaloids and aristolochic acids) before downstream synthesis.
Traditional manufacturing often concentrates hazardous trace constituents alongside target active ingredients, causing acute hepatic or gastrointestinal side effects. Our high-throughput facility deploys supercritical CO2 fluid extraction, macroporous resin adsorption chromatography, continuous countercurrent extraction, and preparative HPLC to selectively harvest target fractions with >98% chromatographic purity, ensuring zero unexpected solvent-induced or thermal-degradation side effects.
Integrated research and production shorten formulation cycles from years to months. With 300+ dedicated bioscientists, MedGence runs dedicated cleanrooms, cell biology suites, and pathogen-free animal housing. Every batch undergoes systematic LD50 testing, acute toxicological clearance, and in vitro safety validation, providing global clients with defensible Certificate of Analysis (CoA) documentation verified against USP, EP, and ChP standards.
How Modern Phytopharmacology Bridges Ancient Empirical Medicine and Evidence-Based Safety Toxicology.
Over the past decade, consumer and regulatory scrutiny surrounding herbal medicines, dietary supplements, and botanical drugs has fundamentally shifted. Global health authorities—including the US FDA (21 CFR Part 111 & Part 312), the European Medicines Agency (EMA/HMPC), and the National Medical Products Administration (NMPA)—have escalated requirements regarding toxicological profiles, pharmacokinetic interactions, and adverse event prevention. Historically, botanical extracts were traded as crude multi-constituent powders with undefined impurity profiles, leading to unpredictable consumer reactions such as idiosyncratic drug-induced liver injury (DILI), nephrotoxicity, allergic dermatitis, and competitive cytochrome P450 (CYP3A4/CYP2D6) enzyme inhibition.
Today, premier international healthcare brands prioritize suppliers who provide comprehensive "Side Effect Profiling". Rather than viewing side effects as unavoidable hazards, forward-thinking manufacturers utilize targeted extraction science to detoxify botanical matrices. For instance, classic remedies like Aconitum carmichaelii or Tripterygium wilfordii possess extraordinary anti-inflammatory and analgesic efficacy, yet contain toxic diterpenoid alkaloids or epoxide diterpenoids that cause cardiac arrhythmia or immunosuppression. As an advanced Chinese CRO/CDMO partner, MedGence implements hydrothermal hydrolysis, stereoselective chromatography, and metabolic pathway mapping to neutralize toxic moities while preserving target pharmacological potencies.
Understanding user intent requires unpacking the concrete biomedical settings in which adverse-effect screening and toxicity minimization are deployed:
Building a global, resilient pharmaceutical supply chain requires enterprise-grade research protocols. MedGence’s integrated CRO/CDMO platform eliminates the friction between bench discovery and mass manufacturing:
1. Computational In Silico Toxicity Prediction: Utilizing Quantitative Structure-Activity Relationship (QSAR) and machine learning models, our computational chemistry division screens novel botanical molecules against hERG potassium channel cardiotoxicity, Ames mutagenicity, and CYP450 metabolic profiles before wet-lab synthesis begins.
2. Validated Chromatographic Fingerprinting: Every single plant species exhibits chemical volatility depending on seasonal sunshine, soil microbiome, and post-harvest drying. We establish High-Performance Thin-Layer Chromatography (HPTLC) and Gas Chromatography-Mass Spectrometry (GC-MS) fingerprint patterns, ensuring every delivered lot matches the benchmark toxicity-free safety baseline.
3. Pilot-to-Commercial Transition Under Strict Confidentiality: Moving botanical formulations from 5-liter pilot glass reactors to 10,000-liter stainless steel extraction vessels often generates unexpected degradation products due to shear stress or heat. Our direct engineering oversight guarantees that process control parameters (temperature, pH, residence time, pressure) transfer seamlessly without creating novel pyrolytic side products.
How multinational supply chains evaluate botanical manufacturers on quality audits, ESG governance, and batch-to-batch chemical equivalence.
Global pharmaceutical purchasers demand thorough IND, NDA, and NDI submission documentation. MedGence supplies complete Chemistry, Manufacturing, and Controls (CMC) technical files, validation batches, stability testing under ICH conditions (accelerated and long-term), and rigorous Certificates of Analysis detailing residual solvent clearance, pesticide screens, and heavy metal testing below detectable limits.
The potency of wild or farmed botanical harvests fluctuates radically with seasonal rainfall, sun cycles, and soil mineral composition, causing unpredictable finished product concentrations. Our botanical provenance standardization ensures consistent active molecule ratios while guaranteeing that dormant environmental stress metabolites never cross toxicological thresholds in finished lots.
Contract research and contract manufacturing are founded entirely upon institutional trust. Operating under strict bilateral NDAs and intellectual property ring-fencing, your custom formulas, unique extraction solvents, fraction crystallization parameters, and commercial indications are protected from cross-contamination or unauthorized market disclosure.
Whether your commercial packaging demands micro-filtered concentrated liquids, lyophilized standardized powders, ultrasonic nano-emulsions, softgels, enteric-coated tablets, or oral sachets, our downstream production facilities manage large-volume CDMO demands while maintaining absolute uniformity of physical and chemical parameters.
Expert answers addressing the scientific, operational, and regulatory inquiries of global pharmaceutical buyers and chief scientists.
Our extraction methodology combines chromatographic profiling with targeted molecular fraction separation. First, high-resolution LC-MS/MS identifies all secondary metabolites within the botanical raw material. Second, if any known toxic, hepatotoxic, or allergenic constituents are identified (such as heavy metals, mycotoxins, pesticide residues, or toxic alkaloids), we customize selective macroporous resin columns, liquid-liquid extraction partitions, or membrane filtration systems to capture and remove those specific molecular weights while preserving the beneficial target therapeutic components.
We provide full-spectrum preclinical testing, including Median Lethal Dose (LD50) assays, acute oral toxicity, sub-chronic repeated dose 28-day and 90-day systemic toxicity, skin and ocular irritation testing, bacterial reverse mutation assays (Ames test), in vitro mammalian chromosomal aberration tests, and micronucleus tests. These studies comply with OECD guidelines and generate audit-ready safety portfolios for international regulatory authorities.
Yes. We possess extensive experience modernizing 83 classic Traditional Chinese Medicine (TCM) formulas and registering 56 hospital preparations. A significant portion of this clinical and laboratory work is centered on adjuvant botanical drugs—specifically using standardized polysaccharides, flavonoids, and triterpenes to counteract chemotherapy-induced peripheral neuropathy, combat bone marrow suppression, and mitigate gastrointestinal mucosal toxicity without compromising the primary therapy's cytotoxicity against malignant cells.
Every commercial production campaign undergoes strict chromatographic fingerprinting using HPLC and HPTLC. We establish a verified chemical fingerprint reference standard for every product. Any deviation in peak ratios, retention times, or emergence of unassigned impurity peaks triggers an automated quarantine and investigation. We also execute ICH-compliant accelerated and real-time stability testing to ensure no toxic degradation metabolites form throughout the product's commercial shelf-life.
We provide comprehensive Chemistry, Manufacturing, and Controls (CMC) packages, process validation protocols, analytical method validation reports (ICH Q2(R1)), certificates of origin, non-GMO and allergen statements, heavy metal and pesticide residue test reports, and preclinical safety data packages suitable for submission to the US FDA, EMA, Health Canada, or Australian TGA.
Active pharmaceutical and nutraceutical ingredients can be delivered as ultra-pure concentrated liquids, freeze-dried extract powders, viscous pastes, or volatile supercritical oils. For finished formulations, our CDMO facilities supply oral liquids, hard gelatin and vegetarian capsules, softgels, enteric-coated tablets, dispersible granules, and soluble single-serve stick packs.
Integrate certified botanical research, batch-validated CDMO production, and end-to-end adverse-effect mitigation into your commercial pipeline.
